Mohammad Sadegh Shams Nosrati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Sadegh Shams Nosrati has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Biglari
Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran, Iran
1 shared publication - Alireza Dostmohammadi
Department of Bioinformatics and Computational Biophysics, Faculty of Biology and Centre for Medical Biotechnology (ZMB), University of Duisburg-Essen, 45141 Essen, Germany
1 shared publication - Amir Hesam Nemati
Department of Epidemiology and Biostatistics, Pasteur Institute of Iran, Tehran P.O. Box 13169-43551, Iran
1 shared publication - Federico Zara
Medical Genetics Unit, Istituto Giannina Gaslini, Genoa, Italy; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, Italy, Italy
1 shared publication - Ferruccio Romano
Genomics and Clinical Genetics Unit IRCCS Istituto Giannina Gaslini Genoa Italy
1 shared publication - Francesca Madia
Medical Genetics Unit, Istituto Giannina Gaslini, Genoa, Italy, Italy
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by MDPI AG in Preprints.org
From Genes to Circuits: Modeling Neurodevelopmental Disorders
The genetic architecture of neurodevelopmental disorders (NDDs) is increasingly well described, yet the biological meaning of many variants remains uncertain. A molecular diagnosis may identify the affected gene without explaining how the alteration perturbs brain development or why the same or related variants produce different outcomes. Variant effects are conditioned by dosage, developmental timing, cell identity and the wider genomic, epigenetic and environmental context, while compensatory responses may modify or obscure the phenotype. Functional interpretation therefore depends on linking the molecular defect to the relevant developmental and physiological consequences. This review brings together current knowledge of NDD mechanisms with the experimental and computational strategies used to test that link. No model reproduces the complete disorder, and greater complexity does not necessarily confer greater validity. The most informative system is the one that captures the biological process and developmental window relevant to the question. Concordance across models can strengthen a proposed mechanism, whereas discordant findings may reveal cellular, developmental or species-specific effects that would otherwise be missed. The same standard applies to therapeutic development: correction of a molecular abnormality is meaningful only when it produces durable functional benefit and can be achieved with appropriate central nervous system distribution, dosage and safety. Integrating functional evidence with detailed phenotyping and longitudinal clinical data may improve variant interpretation, distinguish biologically meaningful patient groups and support therapeutic strategies directed at mechanism rather than diagnostic category.
- 13 August 2026
- Published by MDPI AG in Preprints.org
Open AccessFrom Genes to Circuits: Modeling Neurodevelopmental Disorders
The genetic architecture of neurodevelopmental disorders (NDDs) is increasingly well described, yet the biological meaning of many variants remains uncertain. A molecular diagnosis may identify the affected gene without explaining how the alteration perturbs brain development or why the same or related variants produce different outcomes. Variant effects are conditioned by dosage, developmental timing, cell identity and the wider genomic, epigenetic and environmental context, while compensatory responses may modify or obscure the phenotype. Functional interpretation therefore depends on linking the molecular defect to the relevant developmental and physiological consequences. This review brings together current knowledge of NDD mechanisms with the experimental and computational strategies used to test that link. No model reproduces the complete disorder, and greater complexity does not necessarily confer greater validity. The most informative system is the one that captures the biological process and developmental window relevant to the question. Concordance across models can strengthen a proposed mechanism, whereas discordant findings may reveal cellular, developmental or species-specific effects that would otherwise be missed. The same standard applies to therapeutic development: correction of a molecular abnormality is meaningful only when it produces durable functional benefit and can be achieved with appropriate central nervous system distribution, dosage and safety. Integrating functional evidence with detailed phenotyping and longitudinal clinical data may improve variant interpretation, distinguish biologically meaningful patient groups and support therapeutic strategies directed at mechanism rather than diagnostic category.